GlassScriptPhysician profile
Jorge C Garces
NPI 1801854609
$2,136.07
in general payments reported to CMS, 2019-2025
16 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $330 · 2021: $224 · 2022: $275 · 2023: $629 · 2024: $175 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $834 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $834.35 |
| Education | $115.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veloxis Pharmaceuticals, INC. | $347.70 | 2020-2024 | Envarsus |
| Vifor Pharma, INC. | $314.39 | 2019-2021 | |
| Calliditas Therapeutics US INC. | $228.35 | 2023-2024 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $224.52 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $222.06 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $121.83 | 2025 | Ultomiris |
| Sanofi-Aventis U.S. LLC | $112.12 | 2021-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $98.80 | 2023 | |
| Genzyme Corporation | $87.34 | 2020 | |
| Aurinia Pharma U.S., INC. | $87.23 | 2022 | |
| Amgen INC. | $78.49 | 2023 | Tavneos |
| Otsuka America Pharmaceutical, INC. | $77.52 | 2019 | |
| Rockwell Medical, INC. | $60.60 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $29.65 | 2023 | |
| Travere Therapeutics, INC. | $24.79 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $20.68 | 2023 | Nxstage System One |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Garces listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.